PT932411E - Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante - Google Patents

Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante

Info

Publication number
PT932411E
PT932411E PT97904876T PT97904876T PT932411E PT 932411 E PT932411 E PT 932411E PT 97904876 T PT97904876 T PT 97904876T PT 97904876 T PT97904876 T PT 97904876T PT 932411 E PT932411 E PT 932411E
Authority
PT
Portugal
Prior art keywords
adjuvant
stimulating factor
macrofagues
granulocyts
colonies
Prior art date
Application number
PT97904876T
Other languages
English (en)
Inventor
Elke Jager
Alexander Knuth
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of PT932411E publication Critical patent/PT932411E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97904876T 1996-02-09 1997-01-28 Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante PT932411E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/598,909 US6096313A (en) 1996-02-09 1996-02-09 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

Publications (1)

Publication Number Publication Date
PT932411E true PT932411E (pt) 2003-11-28

Family

ID=24397438

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97904876T PT932411E (pt) 1996-02-09 1997-01-28 Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante

Country Status (12)

Country Link
US (1) US6096313A (pt)
EP (1) EP0932411B1 (pt)
JP (1) JP2000506518A (pt)
AT (1) ATE243525T1 (pt)
AU (1) AU723147B2 (pt)
CA (1) CA2244867C (pt)
DE (1) DE69723092T2 (pt)
DK (1) DK0932411T3 (pt)
ES (1) ES2196305T3 (pt)
PT (1) PT932411E (pt)
WO (1) WO1997028816A1 (pt)
ZA (1) ZA97858B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
TR200103266T2 (tr) * 1999-05-13 2002-01-21 American Cyanamid Company Yardımcı kombinasyon formülasyonları
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
TW581709B (en) 1999-10-22 2004-04-01 Asahi Kasei Corp Heat-resistant microporous film
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EE200300172A (et) * 2000-11-10 2003-06-16 Wyeth Holdings Corporation Antigeenne kompositsioon ja adjuvantsegu
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7459085B2 (en) * 2002-10-18 2008-12-02 Asahi Kasei Medical Co., Ltd. Microporous hydrophilic membrane
CN103288920B (zh) 2003-01-30 2015-08-12 苏瓦克有限公司 存活蛋白衍生肽及其用途
EP1691824B1 (en) 2003-11-19 2009-03-11 Survac ApS Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
AU2006209951B2 (en) 2005-02-04 2011-04-14 Survac Aps Survivin peptide vaccine
ES2330013T3 (es) * 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
GB2432723B (en) * 2005-11-25 2010-12-08 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432722A (en) * 2005-11-25 2007-05-30 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432721B (en) * 2005-11-25 2011-06-22 Seiko Epson Corp Electrochemical cell structure and method of fabrication
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR101167392B1 (ko) * 2007-07-27 2012-07-19 이매틱스 바이오테크놀로지스 게엠베하 종양 관련 펩티드의 조성물 및 관련된 항암 백신
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2009253539B2 (en) 2008-04-17 2014-03-20 Io Biotech Aps Indoleamine 2, 3-dioxygenase based immunotherapy
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2012062873A2 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2546358A1 (en) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Methods and reagents for efficient control of HIV progression
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013056716A1 (en) 2011-10-17 2013-04-25 Herlev Hospital Pd-l1 based immunotherapy
WO2013060328A1 (en) 2011-10-26 2013-05-02 Herlev Hospital Ikb based immunotherapy
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
EP2617434A1 (en) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
EP2703482A1 (en) 2012-09-04 2014-03-05 Laboratorios Del. Dr. Esteve, S.A. VSV-HIV viral particles lacking reverse transcriptase functionality and therapeutic applications thereof
ES2639855T3 (es) 2013-12-23 2017-10-30 Exchange Imaging Technologies Gmbh Nanopartícula conjugada a péptidos de unión a CD44
EP3919074A1 (en) 2014-09-17 2021-12-08 IO Biotech ApS Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
US11298413B2 (en) 2015-09-16 2022-04-12 Io Biotech Aps Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
EP3147364A1 (en) 2015-09-28 2017-03-29 Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) Antiviral agents comprising an oligonucleotide-lipid conjugate forming g-quadruplex
AU2017276498A1 (en) 2016-06-10 2019-01-03 Io Biotech Aps CALR and JAK2 vaccine compositions
EP3275462A1 (en) 2016-07-27 2018-01-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Virus-like particles with high-density coating for the production of neutralizing antibodies
CA3141454A1 (en) 2019-05-22 2020-11-26 Aelix Therapeutics, S.L. Dosage regimens for vaccines
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2022017895A1 (en) 2020-07-21 2022-01-27 Rhovac Aps Treatment of residual disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679356A (en) * 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
AU3889997A (en) * 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same

Also Published As

Publication number Publication date
DK0932411T3 (da) 2003-08-18
ES2196305T3 (es) 2003-12-16
JP2000506518A (ja) 2000-05-30
US6096313A (en) 2000-08-01
DE69723092D1 (de) 2003-07-31
AU723147B2 (en) 2000-08-17
AU1755297A (en) 1997-08-28
ZA97858B (en) 1997-08-04
EP0932411A4 (en) 2001-09-26
ATE243525T1 (de) 2003-07-15
DE69723092T2 (de) 2003-12-18
CA2244867C (en) 2003-09-09
EP0932411A1 (en) 1999-08-04
WO1997028816A1 (en) 1997-08-14
CA2244867A1 (en) 1997-08-14
EP0932411B1 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
PT932411E (pt) Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante
MY119403A (en) Novel compounds with analgesic effect.
MY121548A (en) Compounds and methods for the treatment of cancer
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
SE9604786D0 (sv) New compounds
MY122383A (en) Cyclic boroproline compounds
EA199900486A1 (ru) Применение сфингомиелиназы для повышения уровней церамидов в коже и слизистых оболочках, а также содержащие ее дерматологические и косметические композиции, которые удобны для местного применения
GEP20043322B (en) C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
ATE188965T1 (de) Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln
MX9501848A (es) Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
ATE35416T1 (de) Derivate des glycerophosphocholins und glycerophosphoethanolamins, ihre herstellung und verwendung.
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
IL150125A0 (en) Novel compounds
TW198685B (pt)
BG101126A (en) The use of muramylpeptide compounds
FI852730A0 (fi) (pyrrol-1-yl) -fenyl-dihydropyridazinoner, deras framstaellning och anvaendning.
SE8703210D0 (sv) Hudvardskompositioner med keratolytisk och antiinflammatorisk aktivitet
ES8703456A1 (es) Procedimiento para preparar derivados de nitrofurano
GEP20043239B (en) C10 Carbonate Substituted Taxanes as Antitumor Agents
ZA874470B (en) New tetrahydrobenzothiazoles,and the preparation and use thereof
DE69131202T2 (de) Die Verwendung von IL-4 und TNF zur Herstellung eines Medikaments zur Behandlung von Krebszellen
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
IT1251497B (it) Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n,n-dimetiletanolammina, in composizioni dermatologiche
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.